Enjoy complimentary customisation on priority with our Enterprise License!
The global upper respiratory tract infection treatment market size is estimated to grow by USD 2.66 billion at a CAGR of 4.21% between 2023 and 2028.
Top players in the market would be encouraged to concentrate on developing respiratory drugs that treat upper tract infections given the high prevalence of these infections. In the pipeline, a number of late-stage molecules are likely to be launched over the next few years. For instance, Emergo Therapeutics is developing norketotifen, an antagonist of the histamine H1 receptor and mast stabilizer, to treat allergic rhinitis. The drug is currently in a Phase II clinical trial. Hence, such a favorable drug pipeline will boost the growth of the market growth during the forecast period.
To learn more about this report, Request Free Sample
Technavio has segmented the market into Type, Distribution Channel, and Application
It also includes an in-depth analysis of drivers, trends, and challenges. Our report examines historic data from 2018 to 2022, besides analyzing the current market scenario.
The market share growth of the antibiotics segment will be significant during the forecast period. This segment contains antibiotics such as azithromycin, amoxicillin, doxycycline, clarithromycin, erythromycin, and VIBRAMYCIN. The comfortable availability of antibiotics to treat upper respiratory tract infections and their signs will drive the market growth. Upper respiratory tract infections are caused by bacteria such as Streptococcus pneumoniae, Chlamydia pneumonia.
Get a glance at the market contribution of various segments View a PDF Sample
The antibiotics segment was valued at USD 5.82 billion in 2018. Antibiotics are used to treat various symptoms, such as pneumonia, influenza, and other respiratory tract infections. Furthermore, the widespread prevalence of respiratory tract infections across the globe, the increasing resistance of bacteria to non-antibiotic treatments, and the growing awareness among healthcare professionals about appropriate antibiotic usage and the development of new and more potent antibiotics will drive the growth of the antibiotics segment of the market during the forecast period.
Hospital pharmacies work closely with suppliers and pharmaceutical companies to purchase medications needed to treat the upper respiratory tract. These drugs are then stored in pharmaceutical warehouses. Inventory management systems help monitor stock levels and ensure that an adequate supply of respiratory medications is available. Moreover, hospital pharmacies often provide patient education on how to use respiratory medications correctly. This education contributes to better patient adherence and more effective drug distribution. These factors will contribute to the growth of the hospital pharmacies segment, which will drive the growth of the market in focus during the forecast period.
The market has a well-established offline distribution channel that includes various types of retail pharmacy stores, such as drugstores, supermarkets, hypermarkets, and convenience stores. The primary mode of distribution of onychomycosis drugs is through these retail pharmacies, which have a wide geographical presence and are easily accessible to consumers. Moreover, the increasing number of pharmacy stores, supermarkets, and hypermarkets, the ease of availability of OTC/antibiotics drugs across platforms, and the easy accessibility to outlets are estimated to drive the growth of the retail pharmacies segment of the global market during the forecast period
For more insights about the market share of various regions View PDF Sample now!
North America is estimated to contribute 47% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. The North American market is dominated by the US and is driven by increasing rates of upper respiratory tract infection therapeutic. The growing elderly population requires more respiratory drugs and medical services. North America, especially the US and Canada, has an aging population, increasing the incidence of respiratory diseases.
Furthermore, the presence of specialized respiratory care centers and clinics across North America ensures comprehensive care for patients with respiratory conditions, driving demand for respiratory medications. Thus, these factors will propel the US Bilevel Positive Airway Pressure (BiPAP) market during the forecast period. These centers and clinics play a crucial role in providing tailored treatment plans and access to advanced respiratory therapies like BiPAP devices, which are essential for managing conditions such as COPD and sleep apnea. The US BiPAP market benefits from the increasing focus on patient-centric care and technological advancements in respiratory healthcare, facilitating improved patient outcomes and enhanced quality of life. This market growth is supported by the collaborative efforts of healthcare providers, manufacturers, and regulatory bodies to address the evolving needs of respiratory patients across North America.
Buy Now Full Report and Discover More
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 14 market companies, including:
AstraZeneca Plc: The company offers upper respiratory tract and immunolofy treatment that care for patients, moving beyond symptom control to disease modification, remission and, one day cure.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The market is segmented based on various factors related to lung diseases, self-healing diseases, and respiratory diseases such as bronchitis, asthma, and allergic rhinitis. Pneumonia and sinusitis also contribute significantly to this market segmentation. Physical activities play a crucial role in managing these conditions, although patients often experience symptoms such as coughing, wheezing, chest pain, respiratory distress, and shortness of breath. Congestion and, in severe cases, death can occur, highlighting the morbidity associated with these infections. The market includes various generic drugs used for treatment and emphasizes the importance of vaccination and influenza prevention strategies, including antiviral chemoprophylaxis. The geriatric population with weakened immune systems is particularly vulnerable, necessitating caution against overprescribing antibiotics. There are multiple factors influencing market growth. Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges.
Rising demand for over-the-counter drugs is the key factor driving market growth. Patients with colds and coughs often avoid seeing a healthcare professional because the infection can be self-treated with over-the-counter medications. Nasal decongestants such as Afrin (oxymetazoline nasal), Neo-Synephrine (phenylephrine nasal), and Sudafed PE (phenylephrine oral) are some of the over-the-counter drugs that help unclog congested nose.
Moreover, in the case of allergic rhinitis, over-the-counter pills such as Claritin, Alavert, Astelin, and Astepro do not require a written prescription from a healthcare professional and can be directly purchased from a pharmacy. Thus, rising demand for OTC drugs will have a positive impact on the growth of the global market during the forecast period.
The development of drug-delivery devices to treat upper respiratory tract infections is a primary trend shaping market growth. The development of drug-delivery devices to treat upper respiratory tract infection therapeutic will accelerate market growth. For example, Intersect ENT Inc. (Intersect ENT) is developing a novel device known as ASCEND, an investigational drug-coated sinus balloon. It is designed to deliver corticosteroids directly into sinuses at the time of dilation.
Likewise, Intersect ENTs PROPEL products are the first and only dissolvable implants designed to release mometasone furoate and are approved by the US FDA. PROPEL Contour is indicated for the frontal and maxillary sinuses and PROPEL Mini is indicated for the ethmoid and frontal sinuses. Therefore, the development of drug-delivery devices to treat upper respiratory tract infections will propel the growth of the market during the forecast period.
Side effects of NSAIDs is a challenge that affects market growth. NSAIDs are used to treat upper respiratory tract infections therapeutically. However, these drugs are associated with side effects, which can pose a challenge to the market. NSAIDs such as aspirin, ibuprofen, and naproxen are used to treat the common cold. Common side effects of ibuprofen include stomach upset, mild heartburn, nausea, vomiting, bloating, gas, diarrhea, and constipation.
In addition, NSAIDs can cause an increased risk of adverse gastrointestinal events, including bleeding, ulceration, and perforation of the stomach or intestines. Elderly patients with peptic ulcers are at a high risk of serious gastrointestinal events. Therefore, the side effects of NSAIDs have led to a decrease in patient compliance, which may impede market growth during the forecast period.
Buy Now Full Report and Discover More
The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Market Customer Landscape
The market research report provides comprehensive data (region wise segment analysis), with forecasts and estimates in "USD Billion" for the period 2024 to 2028, as well as historical data from 2018 to 2023 for the following segments
The market is driven by the prevalence of conditions like bronchitis, asthma, and sinusitis. Physical activities play a crucial role in managing these ailments, but symptoms like coughing, wheezing, and chest pain can still occur. Respiratory distress and shortness of breath are common, leading to congestion and, in severe cases, death. The morbidity associated with these conditions imposes a substantial cost burden and highlights the need for effective treatment to reduce hospitalizations and emergency visits. Despite the presence of generic players offering generic drugs, the market faces challenges due to adverse effects and overprescribing antibiotics. Biotechnological advancements have led to the development of respiratory devices such as therapeutic ventilators, inhalers, nebulizers, and oxygen concentrators, aiding in respiratory medical care. Innovative diagnostic tools and clinical trials drive diagnosis accuracy and lung disease management.
Moreover, efforts in health promotion and CRD prevention are vital, especially with the rise in viral infections. Vaccination and influenza prevention strategies are essential for the geriatric population with weakened immune systems. Improvements in healthcare infrastructure and facilities are necessary to address unhealthy lifestyles and enhance physical functioning. The market's focus is on providing effective treatment for upper respiratory tract infections, emphasizing patient awareness and primary care access. Strategies like antiviral chemoprophylaxis and self-healing disease management are integral in combating respiratory droplets transmission and reducing occupational lung risks.
Market Scope |
|
Report Coverage |
Details |
Page number |
170 |
Base year |
2023 |
Historic period |
2018-2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 4.21% |
Market growth 2024-2028 |
USD 2.66 billion |
Market structure |
Concentrated |
YoY growth 2023-2024(%) |
3.46 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 47% |
Key countries |
US, Canada, Germany, UK, and China |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
AstraZeneca Plc, CSL Ltd., GlaxoSmithKline Plc, MD Total Care LLC., Medtronic Plc, Merck and Co. Inc., Novartis AG, Parkway Holdings Ltd., Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi, Teva Pharmaceutical Industries Ltd., The Cleveland Clinic Foundation, and Yashoda Hospitals |
Market dynamics |
Parent market analysis, market growth analysis, Market forecasting, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
View Sample PDF at your Fingertips
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Type
7 Market Segmentation by Distribution Channel
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get the report (PDF) sent to your email within minutes.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.